Real-Time Search-Assisted Multiplexed Quantitative Proteomics Reveals System-Wide Translational Regulation of Non-Canonical Short Open Reading Frames.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
12 06 2023
Historique:
received: 24 03 2023
revised: 24 05 2023
accepted: 07 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Abnormal expression of histone deacetylases (HDACs) is reported to be associated with angiogenesis, metastasis and chemotherapy resistance regarding cancer in a wide range of previous studies. Suberoylanilide hydroxamic acid (SAHA) is well known to function as a pan-inhibitor for HDACs and recognized as one of the therapeutic drug candidates to epigenetically coordinate cancer cell fate regulation on a genomic scale. Here, we established a Real-Time Search (RTS)-assisted mass spectrometric platform for system-wide quantification of translated products encoded by non-canonical short open reading frames (ORFs) as well as already annotated protein coding sequences (CDSs) on the human transciptome and applied this methodology to quantitative proteomic analyses of suberoylanilide hydroxamic acid (SAHA)-treated human HeLa cells to evaluate proteome-wide regulation in response to drug perturbation. Very intriguingly, our RTS-based in-depth proteomic analysis enabled us to identify approximately 5000 novel peptides from the ribosome profiling-based short ORFs encoded in the diversified regions on presumed 'non-coding' nucleotide sequences of mRNAs as well as lncRNAs and nonsense mediated decay (NMD) transcripts. Furthermore, TMT-based multiplex large-scale quantification of the whole proteome changes upon differential SAHA treatment unveiled dose-dependent selective translational regulation of a limited fraction of the non-canonical short ORFs in addition to key cell cycle/proliferation-related molecules such as UBE2C, CENPF and PRC1. Our study provided the first system-wide landscape of drug-perturbed translational modulation on both canonical and non-canonical proteome dynamics in human cancer cells.

Identifiants

pubmed: 37371559
pii: biom13060979
doi: 10.3390/biom13060979
pmc: PMC10296652
pii:
doi:

Substances chimiques

Vorinostat 58IFB293JI
Proteome 0
Histone Deacetylases EC 3.5.1.98
Hydroxamic Acids 0
Histone Deacetylase Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2014 May 29;509(7502):582-7
pubmed: 24870543
Cell Rep. 2018 Jun 26;23(13):3710-3720.e8
pubmed: 29949756
J Proteome Res. 2014 Mar 7;13(3):1757-65
pubmed: 24490786
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33468658
Nat Commun. 2019 Nov 6;10(1):5043
pubmed: 31695040
Gene. 2014 Dec 15;553(2):98-104
pubmed: 25300249
Nat Commun. 2019 Aug 9;10(1):3623
pubmed: 31399583
J Neurooncol. 2011 Nov;105(2):241-51
pubmed: 21598070
Front Biosci (Schol Ed). 2012 Jan 01;4(3):831-9
pubmed: 22202094
Nat Chem Biol. 2013 Jan;9(1):59-64
pubmed: 23160002
J Proteome Res. 2020 May 1;19(5):2026-2034
pubmed: 32126768
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
Mol Cell Proteomics. 2007 Jun;6(6):1000-6
pubmed: 17317662
Nucleic Acids Res. 2018 Jan 4;46(D1):D497-D502
pubmed: 29140531
Sci Adv. 2020 May 20;6(21):eaaz2059
pubmed: 32671205
Front Genet. 2020 Sep 11;11:578011
pubmed: 33024443
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27599530
Science. 2009 Apr 10;324(5924):218-23
pubmed: 19213877
Eur J Pharmacol. 2021 Oct 5;908:174399
pubmed: 34331954
Anal Chem. 2020 May 5;92(9):6478-6485
pubmed: 32250601
Eur J Cancer. 2009 Sep;45(13):2402-11
pubmed: 19553104
Mol Cell Proteomics. 2022 Apr;21(4):100219
pubmed: 35219906
Nat Biotechnol. 2007 Jan;25(1):84-90
pubmed: 17211407
Genome Res. 2004 Oct;14(10B):2048-52
pubmed: 15489325
Nature. 2014 May 29;509(7502):575-81
pubmed: 24870542
Int J Oncol. 2014 May;44(5):1745-55
pubmed: 24626405

Auteurs

Hiroko Kozuka-Hata (H)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Tomoko Hiroki (T)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Naoaki Miyamura (N)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Aya Kitamura (A)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Kouhei Tsumoto (K)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.

Jun-Ichiro Inoue (JI)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Masaaki Oyama (M)

Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH